Clinical Trial Update: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial studying A166 in patients with various HER2-expressing or HER2-amplified cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Cancers with HER2 Expression
• Cervical Cancer
• Colorectal Cancer
• Gastric Cancer Biliary Cancer Cholangiocarcinoma
• HER2 Gene Mutation
• Head and Neck Cancer
• Lip Cancer
• Liver Cancer
• Lung Cancer
• Mouth Cancer
• Mucinous Breast Cancer
• Mucoepidermoid Carcinoma
• Ovarian Cancer
• Pancreatic Cancer
• Peritoneal Carcinoma
• Prostate Cancer
• Rectal Cancer
• Salivary Gland Cancer
• Skin Cancer
• Tongue Cancer
• Urothelial Cancer

Drugs mentioned

• A166

Snippet

Sponsor: Klus Pharma Inc. | Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED